The New Zealand new psychoactive substances regime – a step in the right direction,but questions still remain

Advisory Council on the Misuse of Drugs (ACMD) (2010) Consideration of the Cathinones. London: Home Office.

Baumann MH Partilla JS Lehner KR , et al. (2012) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38: 552–562.

Christin N (2013) Traveling the Silk Road: A measurement analysis of a large anonymous online marketplace. Paper presented at WWW 2013 Conference, Rio de Janeiro, Brazil, 13–17 May 2013, available at: http://www.telegraph.co.uk/health/healthnews/9979948/Legal-highs-should-be-sold-like-alcohol.html (last accessed 30 August 2013)

Collins N (2013) Legal highs ‘should be sold like alcohol’. The Telegraph, 9 April. Available at: http://www.telegraph.co.uk/health/healthnews/9979948/Legal-highs-should-be-sold-like-alcohol.html (last accessed 30/8/2013)

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2013) European Drug Report 2013: Trends and developments. Lisbon, EMCDDA.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Europol 2012 Annual Report on the implementation of Council Decision. Report no. 2005/387/JHA (New drugs in Europe, 2012). Lisbon: EMCDDA.

Evans-Brown M Bellis MA McVeigh J (2011) Should ‘legal highs’ be regulated as medicinal products? Brit Med J 342: d1101.

Hastings G Anderson S Cooke E , et al. (2005) Alcohol marketing and young people’s drinking: A review of the research. J Public Health Policy 26: 296–311.

Hughes B Winstock (2012) Controlling new drugs under marketing regulations. Addiction 107: 1894–1899.

Jones L Bellis MA Dedman D , et al. (2009) Alcohol Attributable Fractions for England. Liverpool, Centre for Public Health.

Karlsson P (2010) Alternatives to the deficit model of adolescent drug use. In: Decorte T Fountain J (eds) Pleasure, Pain and Profit – European Perspectives on Drugs. Lengerich: Pabst Science Publishers, pp. 21–34.

Klein A (2011) Khat deaths – or the social construction of a non-existent problem? A response to Corkery et al. ‘Bundle of fun’ or ‘bunch of problems’? Case series of khat-related deaths in the UK. Drugs (Abingdon Engl) 18: 426–427.

Medicines and Healthcare Products Regulatory Agency (MHRA) (2013) Nicotine containing products. Available at: www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice%E2%80%93M%E2%80%93T/Nicotinecontainingproducts/index.htm (accessed 17 June 2013).

Ministry of Health (2012) Regulatory impact statement - New regulatory regime for psychoactive substances. Wellington, New Zealand: Ministry of Health.

Mithoefer MC Wagner MT Mithoefer AT , et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. J Psychopharmacol 27: 28–39.

Motbey CP Kelly J Clemens KJ , et al. (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. J Psychopharmacol 27: 823–836.

Nutt D (2009) Equasy – an overlooked addiction with implication for the current debate on drug harms. J Psychopharmacol 23: 3–5.

Nutt DJ King LA Phillips LD (2010) Drug harms in the UK: A multicriteria decision analysis. Lancet 376: 1558–1565.

Nutt D King LA Nichol DE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14: 577–585.

Parrott AC (2013) MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational ‘Ecstasy’ users. Neurosci Biobehav Rev 37: 1466–1484.

Reuter P (2012) The dangerous charms of the unknown. Addiction 107: 1902–1903.

Schmidt MM Sharma A Schifano F , et al. (2011) 'Legal highs' on the net-evaluation of UK-based Websites, products and product information. Forensic Sci Int 206: 92–97.

Sumnall HR Evans-Brown ME McVeigh J (2013) Epidemiology and use of novel psychoactive substances. In: Dargan P Wood D (eds) Novel Psychoactive Substances. Waltham Academic Press, pp. 79–105.

Uchiyama N Kawamura M Kikura-Hanajiri R Goda Y (2013) URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227: 21–32.

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2012. Geneva: United Nations.

Watterson LR Kufahl PR Nemirovsky NE , et al. (2012) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol DOI: 10.1111/j.1369–1600.2012.00474.x.

Wilkins C Sheridan J Adams P , et al. (2013) The new psychoactive substances regime in New Zealand: A different approach to regulation. J Psychopharmacol 27: 584–589.